sorafenib has been researched along with 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide) | Trials (2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide) | Recent Studies (post-2010) (2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 158 | 2 | 52 |
| Protein | Taxonomy | sorafenib (IC50) | 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide (IC50) |
|---|---|---|---|
| Adenosine receptor A3 | Homo sapiens (human) | 0.0017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bar-Yehuda, S; Benjaminov, O; Ciuraru, NB; Cohen, S; Farbstein, M; Fishman, P; Fishman, S; Harpaz, Z; Kerns, WD; Medalia, G; Patoka, R; Silverman, MH; Singer, B; Stemmer, SM | 1 |
1 trial(s) available for sorafenib and 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
| Article | Year |
|---|---|
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Sorafenib; Wnt Signaling Pathway | 2013 |